Hematopoietic cell transplantation (HCT) is commonly used for the treatment of many malignant hematologic disorders. When coexisting two hematologic malignancies are diagnosed in the same patient, the therapeutic decision making becomes highly complex. Here we report such a case where allogeneic HCT was performed to address two BM malignancies.
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CASE
A 65-year-old woman presented with anemia and was diagnosed with Durie-Salmon Stage 3A IgA kappa multiple myeloma with 30% plasma cells in the BM. The patient became progressively anemic requiring seven units of RBC transfusions over the five subsequent months. Her BM biopsy 2 months later showed 20% plasma cells as well as 15 to 20% CD34+, CD117+ and myeloperoxidase-positive myeloblasts by flow cytometry. There was also dysplasia and nuclear budding on some erythroid precursors. Cytogenetics showed normal female karyotype. FISH showed three 11q, 17p with 1-2 extra 1q signals (from myeloma panel) and 5q (from myelodysplasia panel) hybridization signals. This was consistent with refractory anemia with excess blasts-2. It was classified as Intermediate-2 based on the International Prognostic Scoring System. She was treated with five cycles of 5-azacytidine plus lenalidomide.
She underwent allogeneic HCT with a conditioning regimen of fludarabine 30 mg/m 2 IV on days − 6 through − 3, melphalan 70 mg/m 2 IV on days − 4 and − 3 plus bortezomib 1.3 mg/m 2 IV on day − 3 followed by allografting from a 34-year-old fully matched unrelated female donor. Her GVHD prophylaxis was tacrolimus plus MTX.
The patient developed grade II acute GVHD initially involving her gut then skin. She was treated with beclomethasone and budesonide with topical corticosteroid for the skin. Sirolimus was added without response, then prednisone was initiated for the treatment of GVHD. Subsequently, narrow band UVB therapy was added for the worsening skin GVHD. GVHD was controlled and systemic corticosteroid was tapered successfully. She achieved stable engraftment. At 18 months after the allogeneic HCT, both myeloma and myelodysplastic syndrome (MDS) are both in remission, and her GVHD is quiescent with ongoing immunosuppression taper.
DISCUSSION
Our case illustrates several important aspects of transplant strategy in patients with dual BM disorders. Firstly, harboring two independent malignant hematologic conditions is uncommon. Simultaneous and concurrent diagnosis of myeloma and MDS prior to the initiation of any therapy appears to be rare. [1] [2] [3] Ortega et al.
3 reported a case with deletion of chromosome 5q in both clones of myeloma and MDS where the patient was treated with lenalidomide with PR. As the incidences of both MDS as well as monoclonal gammopathy as a precursor of multiple myeloma increase with age, it is conceivable that these two separate hematologic processes may occur in the same individual. A group of researchers from Japan reported 14 such cases over a 10-year period and noted relatively stable monoclonal gammopathy over time which likely did not negatively impact MDS prognosis. 4 Secondly, the treatment decision regarding the dual BM disorders may be complex. Allogeneic HCT can be curative for both MDS and multiple myeloma. Zimmerman et al. 5 reported 21 patients with both MDS and concurrent lymphoid malignancy including one patient with multiple myeloma who received allogeneic HCT. In patients with secondary MDS (n = 17), median relapse-free survival and OS were 4.3 months and 6.2 months, respectively. They concluded that patients should not be excluded from consideration for transplant due to concurrent lymphoid malignancies, however, both relapse and non-relapse mortality rates were high suggesting the need for further improvement.
Occurrence of MDS and/or AML in multiple myeloma patients is a well-known phenomenon mostly in the context of prior alkylating agent exposure, autologous HCT, and most recently the use of immunomodulatory agents such as lenalidomide. 6, 7 Several speculations have been made for the pathogenicity of MDS development in patients with multiple myeloma who received alkylating agents. Aside from genomic instability introduced with DNA damaging agents, polymorphism of the EPO gene promotor may have a role in the MDS development. In a nested case-control study, the single-nucleotide polymorphism (SNP) rs1617640 in the EPO promotor was more commonly seen in multiple myeloma patients who developed MDS (27%) vs those myeloma patients who did not develop MDS (12%). This SNP was observed more frequently in MDS patients (25.1%) than in healthy controls (6.3%) in a previous study. 8 This finding may shed light on the susceptibility genes in the development of second malignancies following the diagnosis of myeloma.
In a recent study of a transgenic mouse model expressing MafB in hematopoietic progenitor cells, Vicente-Duenas et al. 9 demonstrated that these mice develop plasma cell neoplasms suggesting a novel mechanism involved in tumorigenesis where progenitor cells (that are different from phenotypic cell of origin) may be epigenetically reprogrammed to become terminally differentiated tumor cells. This study may imply possible novel cell of origin for myeloma at progenitor cell level which could explain the simultaneous or metachronous development of MDS.
In summary, we report a patient with concurrent diagnosis of MDS and multiple myeloma who underwent allogeneic HCT and remains in remission for both hematologic malignancies at 18 months after transplant. Allogeneic HCT is a potential option for eligible patients with dual BM disorders.
